RARE
$48.11
Ultragenyx Pharmaceu
($.11)
(.23%)
RARE
Earnings Whisper ®
N/A
4th Quarter December 2017
Consensus:  ($1.93)
Revenue:  $0.10 Mil
Thursday
Feb 1
4:10 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RARE reports earnings?
Beat
Meet
Miss

Where is RARE's stock price going from here?
Up
Flat
Down
Stock chart of RARE
Analysts
Summary of analysts' recommendations for RARE
Score
Grade
Pivots
Resistance
$52.39
$50.83
$49.47

$47.91

Support
$46.55
$44.99
$43.63
Tweet
Growth
Description
Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.
Peers
CelgeneRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonEndo International plcInterCeptEli LillyZoetisBristol-Myers Squibb